---
schema_version: "secwatch.filing_event.v1"
accession: "0001185185-22-000734"
form_type: "8-K"
ticker: "IGC"
cik: "0001326205"
company_name: "IGC Pharma, Inc."
filed_at: "2022-06-09T23:59:59+00:00"
generated_at: "2026-06-25T03:04:29.718254+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IGC receives U.S. patent (#11,351,152) for CBD-based seizure disorder treatment

## Summary
- Patent covers compositions combining CBD with other compounds to treat seizure disorders and epilepsy in humans and animals.
- Aims to reduce side effects of hydantoin anticonvulsants like phenobarbital by lowering dosing.
- Company plans to pursue veterinarian pathway with observational studies and clinical trials for dogs and cats.
- Approximately 50 million people worldwide affected by epilepsy; ~3.8 million dogs in U.S. suffer from seizures.

## SEC filing metadata
- accession: 0001185185-22-000734
- form_type: 8-K
- ticker: IGC
- cik: 0001326205
- company_name: IGC Pharma, Inc.
- filed_at: 2022-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326205/000118518522000734/0001185185-22-000734-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326205/000118518522000734/indiaglob20220608_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001185185-22-000734
- JSON: https://secwatch.observer/filing/0001185185-22-000734.json
- Plain text: https://secwatch.observer/filing/0001185185-22-000734.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.